October 26, 2020
AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the U.S. Food and Drug...
Source URL: https://www.prnewswire.com:443/news-releases/aeglea-biotherapeutics-announces-us-and-eu-orphan-drug-designations-for-acn00177-for-the-treatment-of-homocystinuria-301159052.html
|
